ALNY

232.27

1.40% -3.29

Handel nachbörslich: 232.27

Alnylam Pharmaceuticals Inc (ALNY)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ALNY? Forum Prognose

Schlusskurs vom Vortag:

$235.56

Offen:

$235.8

24-Stunden-Volumen:

1.56M

Relative Volume:

1.87

Marktkapitalisierung:

$30.18B

Einnahmen:

$2.09B

Nettoeinkommen (Verlust:

$-332.26M

KGV:

-56.10

EPS:

-4.14

Netto-Cashflow:

$16.06M

1W Leistung:

-16.99%

1M Leistung:

-21.51%

6M Leistung:

+55.47%

1J Leistung:

+41.86%

1-Tages-Spanne:

$229.85

$242.49

1-Wochen-Bereich:

$229.85

$271.08

52-Wochen-Spanne:

$141.97

$304.39

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Firmenname

Alnylam Pharmaceuticals Inc

Sektor

Healthcare (1196)

Branche

Biotechnology (683)

Telefon

(617) 551-8200

Adresse

675 WEST KENDALL STREET, CAMBRIDGE, MA

Mitarbeiter

2,100

Twitter

@alnylam

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

ALNY's Discussions on Twitter

Vergleichen Sie ALNY mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-08-16	Hochstufung	Goldman	Neutral → Buy
2024-02-16	Herabstufung	Goldman	Buy → Neutral
2024-02-15	Eingeleitet	Wolfe Research	Peer Perform
2023-12-08	Eingeleitet	Wells Fargo	Equal Weight
2023-10-11	Herabstufung	Oppenheimer	Outperform → Perform
2023-09-29	Eingeleitet	Raymond James	Outperform
2023-05-05	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2023-04-26	Eingeleitet	SMBC Nikko	Neutral
2023-03-21	Eingeleitet	Bernstein	Outperform
2023-01-18	Eingeleitet	Canaccord Genuity	Buy
2022-09-09	Fortgesetzt	Morgan Stanley	Equal-Weight
2022-07-13	Eingeleitet	Cantor Fitzgerald	Neutral
2022-06-27	Herabstufung	Guggenheim	Buy → Neutral
2022-06-07	Eingeleitet	William Blair	Outperform
2022-04-25	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2022-03-01	Eingeleitet	Citigroup	Buy
2022-02-03	Hochstufung	Guggenheim	Neutral → Buy
2022-01-03	Hochstufung	Piper Sandler	Neutral → Overweight
2021-11-22	Hochstufung	Goldman	Neutral → Buy
2021-11-22	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2021-11-01	Hochstufung	Oppenheimer	Perform → Outperform
2021-10-04	Hochstufung	UBS	Neutral → Buy
2021-08-04	Herabstufung	Piper Sandler	Overweight → Neutral
2021-02-22	Herabstufung	Guggenheim	Buy → Neutral
2021-02-12	Herabstufung	Citigroup	Buy → Neutral
2021-02-12	Bestätigt	H.C. Wainwright	Buy
2021-01-25	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2020-09-30	Fortgesetzt	Berenberg	Hold
2020-09-08	Eingeleitet	Citigroup	Buy
2020-08-11	Herabstufung	Oppenheimer	Outperform → Perform
2020-05-13	Eingeleitet	RBC Capital Mkts	Sector Perform
2020-05-07	Herabstufung	JP Morgan	Overweight → Neutral
2020-04-24	Fortgesetzt	Evercore ISI	Outperform
2020-03-19	Eingeleitet	Berenberg	Buy
2019-12-19	Bestätigt	Chardan Capital Markets	Buy
2019-11-20	Eingeleitet	Oppenheimer	Outperform
2019-11-13	Eingeleitet	BofA/Merrill	Buy
2019-05-23	Fortgesetzt	Goldman	Neutral
2019-04-12	Eingeleitet	Evercore ISI	Outperform
2019-03-06	Hochstufung	Evercore ISI	In-line → Outperform
2019-03-05	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2019-01-23	Eingeleitet	UBS	Neutral
2018-10-01	Eingeleitet	Cantor Fitzgerald	Overweight
2018-08-13	Bestätigt	Stifel	Buy
2018-08-07	Hochstufung	Stifel	Hold → Buy
2018-05-04	Bestätigt	Stifel	Hold
2018-03-28	Eingeleitet	Evercore ISI	In-line

Alle ansehen

Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten

01:49 AM

Alnylam Pharmaceuticals' (ALNY) Buy Rating Reiterated at HC Wainwright - MarketBeat

01:49 AM

01:48 AM

Piper Sandler Reiterates Overweight Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat

01:48 AM

11:59 AM

Alnylam releases encouraging interim data on nucresiran for ATTR amyloidosis - Seeking Alpha

11:59 AM

09:26 AM

ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study - Yahoo Finance

09:26 AM

07:34 AM

LMR Partners LLP Lowers Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat

07:34 AM

06:40 AM

Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment - Clinical Trials Arena

06:40 AM

Nov 17, 2024

Alnylam's Nucresiran Achieves 96% TTR Reduction in Phase 1 ATTR Amyloidosis Trial | ALNY Stock News - StockTitan

Nov 17, 2024

Nov 16, 2024

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $294.50 Consensus Price Target from Analysts - MarketBeat

Nov 16, 2024

Nov 15, 2024

Alnylam Pharmaceuticals Enters Oversold Territory (ALNY) - Nasdaq

Nov 15, 2024

Primary Hyperoxaluria Treatment Market Outlook by Examining - openPR

Nov 15, 2024

Alnylam Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com India

Nov 15, 2024

Nov 14, 2024

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Down 23.6% in October - MarketBeat

Nov 14, 2024

Nov 13, 2024

Alnylam Pharmaceuticals To Present At UBS Global Healthcare Conference; Webcast At 11:45 AM ET - Nasdaq

Nov 12, 2024

Baillie Gifford & Co. Decreases Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat

Nov 12, 2024

Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Lowered by Wolfe Research - MarketBeat

Nov 12, 2024

Nov 11, 2024

Los Angeles Capital Management LLC Has $37.68 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat

Nov 11, 2024

Nov 10, 2024

Trading (ALNY) With Integrated Risk Controls - Stock Traders Daily

Nov 10, 2024

5,283 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Acquired by New York State Teachers Retirement System - MarketBeat

Nov 10, 2024

Nov 08, 2024

Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks - Benzinga

Nov 08, 2024

Wellington Management Group LLP's Strategic Reduction in Alnylam Pharmaceuticals Inc - GuruFocus.com

Nov 08, 2024

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Increased by AIA Group Ltd - MarketBeat

Nov 08, 2024

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by State of Alaska Department of Revenue - MarketBeat

Nov 08, 2024

Nov 07, 2024

What is HC Wainwright's Forecast for ALNY FY2024 Earnings? - MarketBeat

Nov 07, 2024

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Robeco Institutional Asset Management B.V. - MarketBeat

Nov 07, 2024

Nov 06, 2024

An RNAi renaissance is creating a new generation of startups - BioPharma Dive

Nov 06, 2024

Upcoming Opportunities in Hereditary Amyloidosis Market: - openPR

Nov 06, 2024

Asset Management One Co. Ltd. Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat

Nov 06, 2024

Van ECK Associates Corp Sells 3,539 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat

Nov 06, 2024

Hemoglobinopathies Market Growth Analysis: Industry - openPR

Nov 06, 2024

Nov 05, 2024

Alnylam's SWOT analysis: biotech stock poised for growth in ATTR-CM market - Investing.com

Nov 05, 2024

Alnylam launches Phase 1 trial of ALN-HTT02 for Huntington’s - Huntington's Disease News

Nov 05, 2024

New York State Common Retirement Fund Sells 3,724,457 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat

Nov 05, 2024

Nov 04, 2024

Alnylam Pharmaceuticals, Inc. Promotes Cynthia Clayton to Vice President of Investor Relations and Corporate Communications - Marketscreener.com

Nov 04, 2024

Alnylam shares remain Buy-rated at H.C. Wainwright, target held steady amid ATTR-CM updates - Investing.com UK

Nov 04, 2024

Alnylam to Webcast Presentations at Upcoming November Investor Conferences - StockTitan

Nov 04, 2024

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Holdings Boosted by Wealth Enhancement Advisory Services LLC - MarketBeat

Nov 04, 2024

Nov 03, 2024

Alnylam Pharmaceuticals (NASDAQ:ALNY) Issues Quarterly Earnings Results - MarketBeat

Nov 03, 2024

Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down - MSN

Nov 03, 2024

Nov 02, 2024

Silvant Capital Management LLC Has $4.45 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat

Nov 02, 2024

Nov 01, 2024

Alnylam Earnings: Demand for Amvuttra Drives Sales; Vutrisiran Regulatory Application Submitted - Morningstar

Nov 01, 2024

Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) - Benzinga

Nov 01, 2024

Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat

Nov 01, 2024

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2024 Earnings Call Transcript - MSN

Nov 01, 2024

Needham & Company LLC Reiterates "Buy" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat

Nov 01, 2024

Alnylam Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St

Nov 01, 2024

AustralianSuper Pty Ltd Invests $1 Million in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat

Nov 01, 2024